Play all audios:
Guidance RESPONDING TO EMERGING COVID-19 VARIANTS OF CONCERN A set of principles for understanding the impact of new variants on antiviral drugs and monoclonal antibodies Get emails about
this page DOCUMENTS RESPONDING TO EMERGING COVID-19 VARIANTS OF CONCERN HTML RESPONDING TO EMERGING COVID-19 VARIANTS OF CONCERN PDF, 305 KB, 17 pages This file may not be suitable for users
of assistive technology. Request an accessible format. If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please
email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use. DETAILS The evolution and spread of the original SARS-CoV-2
virus - and subsequent variants of the virus creating cyclical waves of infection - has demanded the rapid development and deployment of many antiviral therapeutic agents which presents a
unique opportunity to assist in the management of the pandemic. The viral escape mechanisms due to new variants have also presented unique challenges arising from the apparent loss of
activity of therapeutic agents, such as the challenge of generating efficacy data in a timely fashion. To address these challenges, the Antivirals and Therapeutics Taskforce established by
the Department of Health and Social Care, together with academic expert pharmacologists, the UKHSA and the MHRA, held a workshop on 12 September 2022, involving several stakeholders, to
identify knowledge gaps and encourage better utilisation of in vitro and Pharmacokinetic-Pharmacodynamic (PK-PD) analysis that could support the ongoing evaluation of the efficacy of several
products. This document describes the discussions and outputs from the workshop and subsequent interactions. It is intended to assist industry and the developers of products by providing a
framework for the development of antiviral drugs and monoclonal antibodies (mAbs). UPDATES TO THIS PAGE Published 2 February 2023 SIGN UP FOR EMAILS OR PRINT THIS PAGE Get emails about this
page Print this page